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Objectives: Rifampicin, a potent first-line TB drug of the rifamycin group, shows only little activity against the
emerging pathogen Mycobacterium abscessus. Reportedly, bacterial resistance to rifampicin is associated with
polymorphisms in the target gene rpoB or the presence of enzymes that modify and thereby inactivate rifampi-
cin. The aim of this study was to investigate the role of the MAB_0591 (arrMab)-encoded rifampicin ADP-
ribosyltransferase (Arr_Mab) in innate high-level rifampicin resistance inM. abscessus.
Methods: Recombinant Escherichia coli andMycobacterium tuberculosis strains expressingMAB_0591were gen-
erated, as was anM. abscessus deletionmutant deficient forMAB_0591.MIC assays were used to study suscepti-
bility to rifampicin and C25 carbamate-modified rifamycin derivatives.
Results: Heterologous expression of MAB_0591 conferred rifampicin resistance to E. coli and M. tuberculosis.
Rifamycin MIC values were consistently lower for the M. abscessus DarrMab mutant as compared with the
M. abscessus ATCC 19977 parental type strain. The rifamycin WT phenotype was restored after complementa-
tion of theM. abscessus DarrMab mutant with arrMab. Further MIC data demonstrated that a C25 modification in-
creases rifamycin activity in WT M. abscessus. However, MIC studies in the M. abscessus DarrMab mutant suggest
that C25modified rifamycins are still subject tomodification by Arr_Mab.
Conclusions:Our findings identify Arr_Mab as themajor innate rifamycin resistance determinant ofM. abscessus.
Our data also indicate that Arr_Mab-mediated rifamycin resistance inM. abscessus can only in part be overcome
by C25 carbamatemodification.
Introduction
Mycobacterium abscessus, an environmental saprophyte, is one of
themost pathogenic and drug-resistant organisms among rapidly
growing mycobacteria (RGM).1,2 It accounts for 80% of all lung
infections due to RGM, particularly exacerbations of chronic lung
disease in patients with cystic fibrosis or bronchiectasis.M. absces-
sus is also responsible for skin or soft tissue infections, usually fol-
lowing trauma, plastic surgery or aesthetic procedures (tattooing
and body piercing).3–11 Currently, there is no reliable antibiotic regi-
men for the treatment of infections withM. abscessus, as this bac-
terium demonstrates a high level of intrinsic and acquired
resistance to commonly administered antibiotics.2,3,7,11
Rifampicin is a major chemotherapeutic agent of the rifamycin
group.12,13 The rifampicinmechanism of action is based on its abil-
ity to inhibit transcription by binding with high affinity to the rpoB-
encoded b-subunit (RpoB) of the DNA-dependent RNA polymerase
of prokaryotes.14,15 Bacterial rifampicin resistance is mostly
attributed to alterations in rpoB, responsible for decreased affinity
of the RpoB for rifampicin.15–18 Less frequent mechanisms of ri-
fampicin resistance include limited membrane permeability to ri-
fampicin and enzymatic inactivation of rifampicin through
modification processes.19–24
Rifampicin resistance mutations were originally identified and
extensively studied in Escherichia coli and are mapped in four dis-
tinct sequence clusters within the rpoB gene, known as the N-ter-
minal cluster (N) and clusters I, II and III.25–30 It has subsequently
been shown that the majority of rifampicin resistance mutations
occur within an 81bp region of cluster I, denoted as the rifampicin
resistance-determining region, across all bacterial species.28,31–33
InMycobacterium tuberculosis, high-level clinically acquired rifam-
picin resistance is almost always conferred bymutations in rpoB.34
In contrast,Mycobacterium smegmatis, which is naturally resistant
to rifampicin, has rifampicin ADP-ribosyltransferase activity confer-
ring innate rifampicin resistance.22,35,36 Combrink et al.37
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delineated that the mechanism of Arr_Msm-mediated rifampicin
inactivation can be overcome by a series of 3-morpholino rifamy-
cins in which the C25 acetate group of the rifamycin core was
replaced by a bulky carbamate group. The C25 carbamate pre-
vents ribosylation of the adjacent C23 alcohol catalysed by
Arr_Msm and thus C25 rifamycins exhibit improved antimicrobial
activity comparedwith rifampicin againstM. smegmatis.37
WGS revealed that M. abscessus carries a putative ADP-
ribosyltransferase (Arr_Mab), encoded by MAB_0591 (arrMab).
11,38
To date, no experimental data have defined the exact function of
MAB_0591 nor confirmed its association with M. abscessus innate
high-level rifampicin resistance.
We here used heterologous expression of MAB_0591 and tar-
geted deletion ofMAB_0591 inM. abscessus to identify Arr_Mab as
the major relevant rifampicin resistance determinant in the type
strain M. abscessus ATCC 19977. In addition, our finding that
Arr_Mab-mediated rifampicin resistance inM. abscessus can hardly
be overcome by rifamycin C25 carbamate modification has im-
portant consequences for the development of new rifamycin de-
rivatives active againstM. abscessus.
Materials and methods
RpoB amino acid sequence alignment
The RpoB sequences of E. coli K-12, M. tuberculosis H37Rv, M. smegmatis
mc2155 and M. abscessus ATCC 19977 were collected from the National
Center for Biotechnology Information (NCBI) database (http://www.ncbi.
nlm.nih.gov/protein/). Multiple sequence alignment was performed using
the ClustalW2 program (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Bacterial strains and growing conditions
(i) E. coli strains were cultivated in LBmedium at 37 C overnight. Ampicillin
was added to the medium at a final concentration of 120mg/L when ne-
cessary. For all cloning steps, E. coli XL1-Blue or E. coli MC1061 were used,
whereas the E. coli-gfp control strain and E. coli-arrMab testing strain were
used for MIC assays. (ii) M. abscessus strains were grown in Middlebrook
7H9 liquid medium or on LB agar plates at 37 C for 5 days. When needed,
apramycinwas added at a final concentration of 50mg/L. TheM. abscessus
ATCC 19977 type strain, M. abscessus DarrMab mutant strain, M. abscessus
DarrMab-arrMab complemented mutant strain and M. abscessus DarrMab
pMV361-aac(3)IV vector backbone control strainwere used throughout this
study. (iii) The M. smegmatis mc2155 type strain was grown on LB agar
plates at 37 C for 3 days. (iv) M. tuberculosis strains were cultivated in
Middlebrook 7H9 liquid medium or on Middlebrook 7H10 agar plates at
37 C for 2–4 weeks and apramycin was added at a final concentration of
50mg/L when necessary. The M. tuberculosis H37Rv type strain, Mtb-
aac(3)IV control strain and Mtb-aac(3)IV-arrMab testing strain were used in
this study.
Antibiotics
Ampicillin, apramycin, amikacin, isoniazid, rifampicin, rifapentine and rifaxi-
minwerebought fromSigma–Aldrich, Switzerland. The following C25modi-
fied rifamycin derivatives were synthesized according to the literature
protocol:37 (i) 5f, 25-O-desacetyl-(4-methoxybenzylaminocarbonyl) 3-
morpholino rifamycin S; (ii) 5k, 25-O-desacetyl-{C-[3-(2-methoxy-phenyl)-
isoxazol-5-yl]-methylaminocarbonyl} 3-morpholino rifamycin S; and (iii) 5l,
25-O-desacetyl-[C-(3-pyridin-2-yl-isoxazol-5-yl)-methylaminocarbonyl] 3-
morpholino rifamycin S. The identity of the compounds was confirmed by
NMR and MS analysis. Purity of each compound was>97% as analysed by
HPLC. Compounds were dissolved in H2O or DMSO according to the
manufacturer’s recommendations, were filter sterilized, aliquotted into
stock solutions of 5–50g/L and finally stored at20 C.
Expression of MAB_0591 in E. coli
MAB_0591 was amplified from M. abscessus ATCC 19977 genomic DNA
by Phusion High-Fidelity DNA Polymerase PCR (50-ATATATGCTCTTCTA
GTACGATGCCCAACTTTTTGA-30 and 50-TATATAGCTCTTCATGCGTCA
TAGATGACCGCGTTTCC-30). Following initial cloning into the pINIT vector,
the sequence-verifiedMAB_0591 amplicon was inserted downstream of
the arabinose-inducible pBAD promoter into the multicopy expression
vector pBXNH3 via a fragment exchange cloning system.39 The resulting
E. coli MC1061 pBXNH3-arrMab testing strain is referred to as E. coli-
arrMab. As a control, gfp was amplified from the pOLYG-gfp-hyg vector
(50-ATATATGCTCTTCTAGTATCTCGAAGGGCGAGGAGCT-30 and 50-TATATA
GCTCTTCATGCCTTGTACAGCTCGTCCATGCCG-30) and cloned directly into
the pBXNH3 expression vector. The resulting E. coli MC1061 pBXNH3-gfp
control strain expressing gfp is referred to as E. coli-gfp. Gene expression
ofMAB_0591 and gfpwas conducted by induction of 30mL bacterial cul-
tures (OD600¼0.85–1) with L-arabinose at a final concentration of 0.2%
v/v, at 37 C for 4.5 h.
Expression of MAB_0591 in M. tuberculosis
MAB_0591 (including its native promoter) was PCR amplified from
M. abscessus ATCC 19977 genomic DNA using KpnI-linker modified primers
50-AGGGTACCCGGATATGTGCAGCGGCATG-30 and 50-GAGGTACCCACCGAAG
CACTGAAGGTGC-30 and cloned into the KpnI site of the pMV361-aac(3)IV
vector to result in the pMV361-aac(3)IV-MAB_0591 complementing vector.
The control backbone vector [pMV361-aac(3)IV] and the complementing
vector [pMV361-aac(3)IV-MAB_0591] were transformed into the electro-
competent M. tuberculosis H37Rv type strain, as previously described for
Mycobacterium bovis BCG.40 Briefly, 400lL ofM. tuberculosis H37Rv compe-
tent cells were mixed with 1lg of supercoiled plasmid DNA and electropo-
rated in a Bio-Rad Gene Pulser II (settings: 2.5 kV, 1000 Ohms and 25 lF).
Following electroporation, cells were resuspended in 4mL of 7H9-OADC-
Tween 80and incubated for 20h at 37 C. Appropriatedilutionswere plated
on selective agar and after 3 weeks of incubation, single colonies were
picked, restreaked and grown in liquid broth when necessary. The Mtb-
aac(3)IV control strain and the Mtb-aac(3)IV-arrMab testing strain were ob-
tained by positive selection on 7H10plates containing apramycin. The pres-
ence of the aac(3)IV and/or the MAB_0591 gene(s) in these strains was
confirmed by colony PCR.
Deletion of MAB_0591 in M. abscessus
An 1.3 kbp PscI/NotI fragment from position 591427 to 592720 (50arrMab
flanking sequence) and an 1.3 kbp NotI/XbaI fragment from position
593015 to 594322 (30arrMab flanking sequence) were PCR amplified using
genomic DNA from M. abscessus ATCC 19977 [(50-GAAATTACATGT
GTCACGATCTCCTGGACTGCCTC-30, 50-GAAAGCGGCCGCCATGGAAGTACGCA
CCCGATTCG-30) and (50-GATAGCGGCCGCCCGAATTCATGGAAACCTTCCGGG-
30, 50-GTCTAGAGTCCTGTGTGAACAGGTCGGTG-30), respectively)] and step-
wise cloned into the pSE-katG-aac(3)IV suicide vector resulting in the knock-
out vector pSE-katG-aac(3)IV-DMAB_0591. Details on the construction of
theM. abscessus deletion mutant will be described elsewhere (A. Rominski,
P. Selchow and P. Sander, unpublished results). Briefly, pSE-katG-aac(3)IV-
DMAB_0591 was transformed into electrocompetent M. abscessus
ATCC 19977. For electroporation, 100lL of competent cells were mixed
with 1–2lg of supercoiled plasmid DNA and electroporated in a Bio-Rad
Gene Pulser II (settings: 2.5 kV, 1000 Ohms and 25 lF). After electropor-
ation, cells were resuspended in 0.9mL of 7H9 medium and incubated for
5h with constant shaking (1000 rpm) at 37 C. Appropriate dilutions were
subsequently plated on selective agar and after 5 days of incubation, single
colonies were picked, restreaked and grown in liquid brothwhen necessary.
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Transformants were selected on LB agar plates containing apramycin and
identified by aac(3)IV PCR. Single crossover transformants were identified
by Southern blot analysis with a 0.2 kbp EcoRI 50arrMab DNA probe (the
same probe was also used for all subsequent Southern blot analyses) and
subjected to counterselection on LB agar plates containing isoniazid
(32mg/L). Single colonies were screened for deletion of MAB_0591 by PCR
and the genotype was finally confirmed by Southern blot analysis. In this
way, a 0.3 kbp region of the MAB_0591was deleted. For complementation
of the M. abscessus DarrMab mutant with MAB_0591, the previously
described complementation vector pMV361-aac(3)IV-MAB_0591 was
transformed into theDarrMabmutant strain. Transformationwas verified by
Southern blot analysis.
Susceptibility testing of M. tuberculosis strains
Drug susceptibility testing (DST) was performed using the MGIT 960 system
as recommended by the manufacturer41 and the results were interpreted
as described previously by Springer et al.42 Briefly, 0.5mL dilutions of posi-
tive MGIT vials of the Mtb-aac(3)IV control strain and the Mtb-aac(3)IV-
arrMab testing strain were inoculated into fresh vials containing constant
levels of apramycin for plasmid maintenance and different concentrations
of the test drugs.43 Rifampicin was tested at concentrations of 1, 4 and
20mg/L, while the control drug isoniazid was tested at concentrations of
0.1, 1, 3 and 10mg/L. For the drug-free growth control, the bacterial work-
ing suspensionwas diluted 1:100with sterile NaCl and 0.5mL of the diluted
working suspension was inoculated into the tube (proportion testing).44 All
MGIT tubes were incubated in the MGIT 960 instrument and monitored
using EpiCenter (version 5.53) software equipped with the TB eXiST module
(BectonDickinson).
Rifampicin Etest
Bacterial suspensions of M. abscessus strains ATCC 19977, DarrMaband
DarrMab-arrMab were adjusted to a turbidity equivalent to that of a 0.50
McFarland standard and subsequently spread on LB agar plates using a
sterile cotton swab. Then, a rifampicin Etest strip (bioMérieux, Switzerland)
was placed on each plate and plates were incubated for 5 days at 37 C.
The point of intersection between bacterial growth and the Etest device
was read as theMIC value.
MIC assays
MIC assays were performed according to CLSI guidelines.45 Working solu-
tions were prepared by diluting the antibiotic stock solutions in CAMHB (pH
7.4) (Becton Dickinson, Switzerland) to a concentration corresponding to
twice the desired final concentration [working solutions of 128, 512 and
1024mg/L were prepared when the highest concentrations tested in the
MIC assay were 64, 256 and 512mg/L, respectively (Table 1 and Table 3)].
By using CAMHB in sterile 96-well microtitre plates (Greiner Bio-One,
Switzerland), 2-fold serial dilutions of the working solutions were prepared.
A positive growth control lacking antibiotic and a sterile negative control
containing only CAMHB were included in each 96-well microtitre plate. For
the preparation of the inoculum, three to four colonies from each bacterial
strain grown on LB agar were transferred into a glass tube containing 2mL
of NaCl using a sterile cotton swab. In order to achieve a final inoculum titre
of 1–5105 cfu/mL, all bacterial suspensions were adjusted to a turbidity
equivalent to that of a 0.50 McFarland standard and subsequently diluted
in CAMHB. The final test volume in each well of the microtitre plate was
0.1mL. The correct titre of each inoculum was checked by obtaining cfu
counts on LB agar plates. All microdilution plates were capped with adhe-
sive sealing covers and incubated at 37 C for (i) 16h for E. coli strains and
(ii) 3, 5, 7 and 12 days forM. abscessus andM. smegmatis strains, before the
MIC values were assessed by visual inspection. All MIC assays were con-
ducted in triplicate.
Results and discussion
Analysis of the RpoB rifampicin resistance sequence
clusters from M. abscessus
To investigatewhether innate rifampicin resistance inM. abscessus
(MIC: 128mg/L) is associated with polymorphisms in the RNA
polymerase b-subunit, we aligned the RpoB amino acid
sequence of M. abscessus ATCC 19977 with those of E. coli K-12
and M. tuberculosis H37Rv, known to be naturally susceptible to
rifampicin,13,16 andM. smegmatismc2155 that has no polymorph-
ism in its rpoB gene corresponding to any known rifampicin resist-
ance genotype,35 but is naturally resistant to rifampicin through
ADP-ribosylation of rifampicin.22,36 Our analysis revealed no poly-
morphism known to confer rifampicin resistance within all four (N,
I, II and III) rifampicin resistance sequence clusters of
M. abscessus RpoB (Figure 1), suggesting that other mechanisms
are involved in the high intrinsic rifampicin resistance of
M. abscessus. Possible mechanisms include efflux of rifampicin, di-
minished uptake of rifampicin and enzymatic degradation or
modification of rifampicin.19–23 The latter resistance
mechanism has been studied in M. smegmatis and
Legionella pneumophila.22,23 A recent genome analysis suggested
that M. abscessus carries a putative rifampicin ADP-
ribosyltransferase (Arr_Mab),38 encoded by MAB_0591 (arrMab).
MAB_0591 has 66% amino acid sequence identity with the M.
smegmatis ADP-ribosyltransferase that modifies rifampicin.
However, Table S1 (available as Supplementary data at JAC
Online), which lists the MIC values for selected mycobacterial
standard strains42,46,47 as well as information about the presence
or absence of ADP-ribosyltransferase-like protein in these species,
shows that a direct correlation between rifampicin MIC and the
presence or absence of ADP-ribosyltransferase-like proteins does
not exist.M. tuberculosis andMycobacterium lepraewere predicted
to havenoADP-ribosyltransferase-like proteins andare susceptible
to rifampicin (MIC:<1mg/L).42,47 ADP-ribosyltransferases were
predicted to be present in M. abscessus (M. abscessus subsp.
abscessus and M. abscessus subsp. bolletii) and Mycobacterium
fortuitum and these species are resistant (MIC:64mg/L).46
In contrast, the presence of putative ADP-ribosyltransferases in e.g.
Mycobacteriumphlei, Mycobacterium gilvum and Mycobacterium
marinum does not correlate with high rifampicin MIC levels
(MIC:<0.5mg/L).46 Therefore, a functional role of ADP-
ribosyltransferases in rifampicin resistance has to be addressed ex-
perimentally. By using ADP-ribosyltransferase of M. smegmatis
mc2155 in a BLASTP search, we identified also other, non-
mycobacterial species predicted to possess ADP-
ribosyltransferase-like proteins (Table S2). Interestingly, myco-
bacterial ADP-ribosyltransferases showhomology to the catalytic
domain of exotoxin A from Pseudomonas aeruginosa,48,49
Table 1. DST results of E. coli expressingMAB_0591a






pointing to a putative role of mycobacterial
ADP-ribosyltransferases as virulence factors. However, within this
study we exclusively focus on the role of MAB_0591 in rifamycin
resistance.
Heterologous expression of MAB_0591 in E. coli and
M. tuberculosis
To study if rifampicin resistance inM. abscessus is due to arrMab, we
clonedMAB_0591 and expressed the recombinant protein in two ri-
fampicin-susceptible hosts, E. coli16 andM. tuberculosis.50 First, we
addressed the question whether induced expression of MAB_0591
would confer rifampicin resistance in a non-mycobacterial heterol-
ogous host. Arr_Mab was recombinantly expressed by the multi-
copy pBXNH3-arrMabvector in E. coli MC1061 under the control of
the L-arabinose-inducible pBAD promoter. The E. coli-gfp control
strain and the E. coli-arrMab testing strain were generated following
transformation with the pBXNH3-gfp and pBXNH3-arrMab vectors,
respectively. The recombinant strains were subsequently tested
Figure 1. Rifampicin resistance regions of RpoB and their association with the interactions between rifampicin and the prokaryotic RNA polymerase
(RNAP). (a) The bar at the top illustrates the RNAP b-subunit from E. coli. Directly above, its amino acid numbering is indicated. Dark red lines within
the bar indicate the positions of the four clusters [N-terminal (N) and clusters I, II and III (I, II and III)] where the rifampicin resistance-conferring al-
terations are identified across all bacterial species.24–30 Directly below follows the amino acid sequence alignment spanning the rifampicin resistance
regions of E. coli K-12, M. tuberculosis H37Rv, M. smegmatismc2155 and M. abscessus ATCC 19977 RpoB. Amino acid substitutions that confer rifampi-
cin resistance are shown as coloured triangles above and below the alignment, respectively. The possible substitutions for each position are men-
tioned in single amino acid code in columns directly above (for E. coli) or below the coloured triangles (for M. tuberculosis). The yellow triangles
represent the residues that interact directly with rifampicin binding. In contrast, the red triangles indicate residues that are positioned too far away to
have direct interaction with rifampicin. The blue triangles show the positions that are substituted with the highest frequency amongM. tuberculosis ri-
fampicin-resistant isolates.31 The green triangles show a residue that is directly interacting with rifampicin, but no substitutions have been reported
at this position, probably because they would be fatal for the bacterium.15 (b) Using the same colour code for the amino acid positions as above, the
residues of direct interaction with rifampicin are shown (yellow, blue and green triangles). Hydrogen bonds formed between an RpoB residue and ri-
fampicin are depicted as broken lines and residues that form van der Waals interactions are indicated in zigzag circles. Numbering of the residues is
according to E. coli positions.15 RIF, rifampicin.




1.0mg/L 4.0mg/L 20.0mg/L 0.1mg/L
Mtb-aac(3)IV S S S S
Mtb-aac(3)IV-arrMab R R R S
S, susceptible; R, resistant.
aProportion method using the MGIT 960 system.
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Figure 2. Genotypic analyses of theM. abscessus arrMablocus. (a) Schematic drawing of genotypes and recombination events. (b) Southern blot analysis
confirms the deletion of MAB_0591 from the genome of M. abscessus. Genomic DNA of M. abscessus ATCC 19977 (1), M. abscessus transformant with
arrMab targeting vector [pSE-katG-aac(3)IV-DMAB_0591] prior to (2) and after KatG-dependent isoniazid counterselection (3) and after transformation
of counterselected mutant with arrMab complementation vector (4) was digested with EcoRI and probed with a fragment from the 5
0arrMab flanking re-
gion. Based on M. abscessus genome annotation and vector sequence, the pattern is consistent with hybridization to a 2.65 kbp fragment of the WT
parental strain, to the 2.36 and 7.45 kbp fragments after site-specific homologous recombination [single crossover (sco)], to a 2.36 kbp fragment of the
DarrMabmutant (D) and to the 2.36 and 3.65 kbp fragments of theM. abscessus DarrMab-arrMab complementedmutant strain (C). M, molecular marker.
Rominski et al.
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against rifampicin in MIC assays. The E. coli-arrMab testing strain
was highly resistant to rifampicin with MIC values >512mg/L,
while the E. coli-gfp control strain remained susceptible to rifampi-
cin (MIC: 4mg/L) (Table 1). These results confirm that Arr_Mab
plays a critical role as a rifampicin resistance determinantwhenex-
pressed in the rifampicin-susceptible E. coli host. We hypothesize
that Arr_Mab modifies rifampicin by ADP-ribosylation at the hy-
droxyl group of C23, as previously shown for Arr_Msm,48 and that
thismodification interfereswith target binding.
Next, we studiedwhether arrMab confers rifampicin resistance in
amycobacterial host,M. tuberculosis. In order to simulate veritable
levels of Arr_Mab expression, we expressed MAB_0591 under con-
trol of its native promoter. The single-copy integrating plasmids
pMV361-aac(3)IV and pMV361-aac(3)IV-MAB_0591 were engin-
eered and transformed into the rifampicin-susceptible M. tubercu-
losisH37Rv strain (MIC:<1mg/L).42 The aac(3)IV gene that confers
resistance to apramycin was used as a positive selection marker.
The resulting strains referred to as Mtb-aac(3)IV control strain and
Mtb-aac(3)IV-arrMab testing strain, respectively, were subjected to
DST using the MGIT 960 system equipped with EpiCenter TB eXiST
software. Susceptibility to different concentrations of rifampicin (1,
4 and 20mg/L) and the non-substrate control drug isoniazid (0.1,
1, 3 and 10mg/L) was determined. TheMtb-aac(3)IV control strain
was, as expected, susceptible to both rifampicin and isoniazid at all
concentrations tested (MIC: rifampicin<1.0mg/L; isonia-
zid<0.1mg/L). In contrast, the Mtb-aac(3)IV-arrMab testing strain
was specifically resistant to rifampicin, even at the highest concen-
tration tested (MIC:>20mg/L), but remained susceptible to the
unrelated control drug isoniazid (MIC:<0.1mg/L) (Table 2). These






Figure 3. Contribution ofMAB_0591 to rifampicin resistance inM. abscessus.
Rifampicin susceptibility of the (a) M. abscessus ATCC 19977WT strain,
(b)M. abscessusDarrMabmutant and (c)M. abscessus DarrMab-arrMab comple-
mented mutant strain was examined by Etest. The picture of the rifampicin
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to rifampicin, but not to other drugs, when expressed in a rifampi-
cin-susceptiblemycobacterial host.
Generation of M. abscessus MAB_0591 deletion mutant
Heterologous expression ofMAB_0591 indicated that arrMab is able
to confer rifampicin resistance to a susceptible host; however, its
role in innate rifampicin resistance inM. abscessus remained to be
determined.We recently developed tools for geneticmanipulation
of M. abscessus (A. Rominski, P. Selchow and P. Sander, unpub-
lished results) and wished to exploit this technique to generate an
M. abscessus MAB_0591 deletionmutant. Thismutantwould allow
us to directly address the role of MAB_0591 in innate rifampicin re-
sistance. The arrMab deletion mutant was constructed by trans-
formation of M. abscessus ATCC 19977 with suicide plasmid pSE-
katG-aac(3)IV-DMAB_0591 applying apramycin positive selec-
tion51 and a katG-dependent isoniazid counterselection strategy
that we previously established (A. Rominski, P. Selchow and P.
Sander, unpublished results) (Figure 2a). Deletion of MAB_0591
was confirmed by Southern blot analysis (Figure 2b). A comple-
mented mutant strain was constructed by transformation of the
M. abscessus DarrMab mutant with the complementation vector
pMV361-aac(3)IV-MAB_0591 expressing Arr_Mab. The
complemented mutant strain is referred to as M. abscessus
DarrMab-arrMab. Genetic complementation was confirmed by
Southern blot analysis (Figure 2b).
DST of M. abscessus DMAB_0591
For determination of the DarrMabmutant’s phenotype, a rifampicin
Etest was carried out with M. abscessus ATCC 19977, M. abscessus
DarrMab mutant and M. abscessus DarrMab-arrMab complemented
strain. Etest results after 5 days of incubation at 37 C revealed
high-level rifampicin resistance in M. abscessus ATCC 19977
(MIC:>32 mg/L). In contrast, the DarrMab mutant showed suscep-
tibility to low rifampicin concentrations (MIC:0.5mg/L).
Rifampicin resistance was restored upon complementation of the
DarrMab mutant strain with arrMab (MIC:>32mg/L; Figure 3). MIC
values were subsequently determined in detail for rifampicin, rifa-
pentine and rifaximin. M. abscessus ATCC 19977, M. abscessus
DarrMab, M. abscessus DarrMab-arrMab complemented mutant,
M. abscessus DarrMab pMV361-aac(3)IV vector backbone control
strain and M. smegmatis mc2155 were subjected to DST. For
M. abscessus DarrMab, the MICs of all rifamycins were consistently
and significantly lower than for the M. abscessus ATCC 19977WT








































































Figure 4. Rifampicin and the 5f: 25-O-desacetyl-(4-methoxybenzylaminocarbonyl) 3-morpholino rifamycin S, 5k: 25-O-desacetyl-{C-[3-(2-methoxy-
phenyl)-isoxazol-5-yl]-methylaminocarbonyl} 3-morpholino rifamycin S and 5l: 25-O-desacetyl-[C-(3-pyridin-2-yl-isoxazol-5-yl)-methylaminocarbonyl]
3-morpholino rifamycin S, C25 carbamate rifamycin derivatives, which are numbered per the original work37 for ease of comparison. RIF, rifampicin.
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Arr_Mab (Table 3). Transformation of theM. abscessusDarrMabmu-
tant with arrMab restored WT levels of rifamycin resistance while
transformation with the empty vector backbone did not.
Expectedly, amikacin MICs were independent of the arr genotype.
These findings identify Arr_Mab as the major rifamycin resistance
determinant inM. abscessus.
DST of C25 modified rifamycin derivatives
Carbamate modification at the C25 position of the rifamycin core
has been shown to improve antimicrobial activity againstM. smeg-
matis mc2155.37 We wanted to test whether these compounds
also overcome rifamycin resistance in M. abscessus. C25 modified
rifamycin derivatives 5f, 5k and 5l (Figure 4) were custom synthe-
sized and tested for antimicrobial activity. The compounds showed
potent activity against M. smegmatis—on average these com-
pounds were 100–200-fold more active than rifampicin. These re-
sults confirm former findings that C25 modified rifamycins
apparently are resilient tomodification byArr_Msm. The C25modi-
fied rifamycins also showed increased activity in M. abscessus as
compared with rifampicin, rifapentine and rifaximin (Table 3). Of
note, C25modification not only increases rifamycin activity against
the M. abscessus WT, but also against the M. abscessus DarrMab
mutant, although to a lesser extent. These data indicate that the
increased activity of C25 rifamycin derivatives is only partially due
to resilience to Arr_Mab modification. Compared with compounds
5f and 5k, we observed little time-dependent increase in the MIC
values of compound 5l for WT M. abscessus and the M. abscessus
DarrMab-arrMab complemented mutant, indicating that 5l is prob-
ably least modified by Arr_Mab, but still WT MIC values are high
(4mg/L; 16-fold higher than against theDarrMabmutant).
Conclusions
Taken together, our study identified Arr_Mab as the major deter-
minant of innate rifamycin resistance inM. abscessus.Our data indi-
cate significant species-specific differences in rifamycin C25-
mediated resilience for Arr_Msm and Arr_Mab, since Arr_Mab-medi-
ated rifamycin resistance canonly partly be overcomeby C25modi-
fication. These findings testify to the need to develop novel
compounds that are able to escape Arr_Mab-mediated rifamycin
resistance in M. abscessus. Structural similarity between Arr_Msm
and protein ADP-ribosyltransferases, prominently domain III of
P. aeruginosa exotoxin A, have been described.48,49 These structural
features are also conserved in Arr_Mab. Therefore, it is tempting
to speculate on a dual role of Arr_Mab in drug resistance and
virulence.
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